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plantation, Burke et al. present their ﬁndings on the efﬁcacy
of allogeneic hematopoietic stem cell transplantation (HCT)
in patients with high-risk childhood acute myelogenous
leukemia (AML). This limited single-institution study
demonstrates that patients with high-risk disease (as
deﬁned by cytogenetics/molecular markers) who received
allogeneic HCT in ﬁrst compete remission (CR) have a favor-
able outcome, similar to those with standard-risk disease.
The role of HCT as consolidation therapy for childhood
AML has evolved signiﬁcantly since Woods et al. ﬁrst
demonstrated that children who received allogeneic HCT
from related donors had an improved outcome compared
with chemotherapy recipients [1]. This study further
demonstrated that pretransplantation chemotherapy can
affect posttransplantation survival; patients who received
more intensive induction chemotherapy had a signiﬁcantly
lower rate of relapse and more favorable survival after HCT,
suggesting that quality of remission (lower residual disease)
was an important determinant of post-HCT survival. In this
study, although HCT carried higher treatment-related
mortality, lower relapse resulted in more favorable
outcomes in HCT recipients. This seminal study led to the
change in the standard of care in childhood AML in the
United States, where patients with newly diagnosed AML
with suitably matched related donors were allocated to
receive HCT in ﬁrst CR. Subsequent studies (Children’s
Cancer Group 2961 and Children’s Oncology Group 03P1
pediatric AML trials) allocated all patients with a matched
family donor to receive HCT in ﬁrst CR [2,3]. With the
improvements in HLA typing and supportive care, and with
broader availability of suitable donors, unrelated HCT has
been more broadly used in patients in ﬁrst CR. Further, re-
evaluation of the role of stem cell transplantation in AML
in the context of emerging prognostic factors has changed
the utility of HCT from a biologic allocation based on donor
availability to a more risk-appropriate therapeutic allocation
aimed at improving outcome while minimizing risk and
toxicity. In this risk-based allocation to HCT, patients withFinancial disclosure: See Acknowledgments on page 1003.
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http://dx.doi.org/10.1016/j.bbmt.2013.05.009favorable disease would not receive HCT in ﬁrst CR, whereas
those identiﬁed to be at high risk of relapse are offered
a transplantation in ﬁrst CR, before an impending relapse.
There has been strong rationale to support this approach,
where in patients who have favorable survival rates with
chemotherapy alone, HCT is reserved for postrelapse
management, sparing the majority of patients (>70%) from
the short-term and long-term toxicities of allogeneic HCT.
Further, as use of HCT from the best available donor in
second or subsequent CR remains the standard of care for
relapsed AML, for those who are at extremely high risk of
relapse after an initial remission, awaiting relapse may
eliminate any hope of achieving a second CR, thus justifying
HCT when remission is achieved and before almost inevi-
table relapse. Such a risk-based therapy allocation is an
attractive therapeutic model, but its utility is entirely
dependent on the availability of clinically informative
prognostic markers. Until recently, cytogenetic alterations
were the only means of risk identiﬁcation in AML, where
those with core binding factor AML were shown to have
a lower risk of relapse, and those with monosomy 7 (-7), or
monosomy5/deletion 5q(-5/del5q) were at high risk of
failure. However, the majority of children with AML lack
clinically informative karyotypes and are not amenable to
risk-based therapy allocation based solely on cytogenetic
subgroups.
More recently, somatic mutations in several genes (FLT3,
NPM, CEBPA) have been shown to correlate with outcome
[4-6], where those patients with FLT3 internal tandem
duplications (FLT3/ITD) with high allelic ratio have a high
rate of failure [4], and those with NPM or CEBPA mutations
have a lower risk of relapse and more favorable outcome.
Cumulatively, clinically signiﬁcant cytogenetic alterations or
somatic mutations account for nearly 35% of cases of AML in
children, leaving more than one-half of children with AML
without a prognostic biomarker. Although other clinically
signiﬁcant mutations have been demonstrated in adult AML,
such mutations are either not seen in childhood AML (IDH1,
DNMT3A mutations) [7,8] or are not independently prog-
nostic (WT1 mutations) [9].
Initial response to chemotherapy has been used to predict
outcome in patients with leukemias. In patients with AML
without an informative genomic biomarker, response to
therapy as deﬁned by multidimensional ﬂow cytometry
(MDF) can provide a powerful tool for risk identiﬁcation.
Studies utilizing sensitive second-generation MDF tech-
nology have shown that in standard-risk patients, presence
of residual disease (RD) after the initial course of chemo-
therapy was highly associated with eventual relapse [10,11].
Combining the molecular risk factors with the
postinduction response assessment by MDF allows risk
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Figure 1. Incorporation of cytogenetic, molecular, and multidimensional ﬂow cytometry data creates a 2-tier risk stratiﬁcation schema. Informative cytogenetics and
mutation data provide a 3-tier risk stratiﬁcation schema, where approximately 35% of patients have either low-risk (CBF AML, NPMcþ or CEBPA mutations) or high-
risk (-7, -5/del5q or FLT3/ITD high AR) disease, and the remaining patients without informative markers are considered to have standard risk. Presence or absence of
residual disease after induction chemotherapy can identify patients at high or low risk of relapse in the standard risk patients. Use of cytogenetic, molecular, and
multidimensional ﬂow cytometry data can be used to assign risk status to nearly all patients with AML.
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informative molecular markers are assigned to the appro-
priate risk class and those without such markers (standard
risk) are assigned based on the presence or absence of RD at
the end of induction chemotherapy. Such an approach allows
appropriate risk-based therapy allocation for nearly all
patients by creating a 2-tier risk-allocation system where
patients are assigned to either the high-risk (cytogenetic/
molecular high risk or standard risk with RD) or low-risk
(cytogenetic/molecular low risk or standard risk without
RD) arm based on the most comprehensive set of prognostic
data available (Figure 1). This 2-tier risk stratiﬁcation schema
was recently incorporated into the ongoing Children’s
Oncology Group phase III AML trial.
The manuscript presented by Burke et al. highlights the
potential beneﬁt of allogeneic stem cell transplantation in
high-risk AML using contemporary donor source, condi-
tioning, and supportive care to optimize outcome by mini-
mizing treatment-related mortality and relapse [12]. It is
especially notable that more than one-half of high-risk AML
patients received double cord transplantation, shown to be
associated with lower risk of relapse [13,14], which, if vali-
dated, provides additional tools for targeting high-risk AML
patients. Some studies have brought into question the efﬁ-
cacy of allogeneic stem cell transplantation for high-risk AML
[15]; however, unless a randomized trial to assess the efﬁ-
cacy of HCT in this high-risk population can be devised
(unlikely), efforts to harness and optimize the graft-versus-
leukemia effect of allogeneic HCT need to continue to
improve the survival in this very high risk patient
population.
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